Cenerimod

Phase 3Small molecule

VViatris Innovation GmbH

Cenerimod is one of 70 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Lupus NephritisActive, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Lupus NephritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Medrol

Pfizer

Phase 3

5 3

Stelara

Johnson & Johnson

Phase 3

3 4

Rayos

RRoxane Laboratories

Phase 3

6 5

Depo-Provera

Cellcept

Benadryl

3 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 9

Imuran

LLegacy Health System

Phase 3

2 10

Rapamune

PPrism Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Systemic Lupus Erythematosus

NCT05648500

Phase 3Active, not recruiting

Systemic Lupus Erythematosus

NCT05672576

Q1 2030

Phase 3Recruiting

Lupus Nephritis

NCT07201129

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus6 trials

A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)

Enrolling by invitation·VViatris Pharmaceuticals Co., Ltd.·Phase 2·NCT07266090·15 enrolled

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Completed·VViatris Innovation GmbH·Phase 2·NCT03742037·427 enrolled

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Enrolling by invitation·VViatris Innovation GmbH·Phase 3·NCT06475742·680 enrolled

Show 3 more trials

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Recruiting·VViatris Innovation GmbH·Phase 3·NCT05648500·420 enrolled

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Completed·VViatris Innovation GmbH·Phase 1/2·NCT02472795·105 enrolled

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Active, not recruiting·VViatris Innovation GmbH·Phase 3·NCT05672576·451 enrolled

Oral1 trial

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT04052360·20 enrolled

Lupus Nephritis1 trial

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

Recruiting·VViatris Innovation GmbH·Phase 3·NCT07201129·300 enrolled

Women1 trial

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Completed·VViatris Innovation GmbH·Phase 1·NCT04255277·97 enrolled

Trial1 trial

A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants

Active, not recruiting·VViatris Innovation GmbH·Phase 1·NCT07301723·6 enrolled

3 more indications

Impairment1 trial

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Completed·VViatris Innovation GmbH·Phase 1·NCT05004311·16 enrolled

Hepatic Impairment1 trial

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Completed·VViatris Innovation GmbH·Phase 1·NCT04819464·24 enrolled

Unspecified1 trial

A Study to Evaluate Cenerimod in Healthy Male Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT02914223·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Cenerimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenerimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenerimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Viatris Innovation GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VViatris Innovation GmbH

Cenerimod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2030

Trials by Indication[1]

Systemic Lupus Erythematosus6 trials

Oral1 trial

Lupus Nephritis1 trial

Women1 trial

Trial1 trial

Impairment1 trial

Hepatic Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News